NEW YORK (GenomeWeb News) – Transgenomic said in a document filed with the US Securities and Exchange Commission this week that its shareholders have approved an increase in the number of authorized shares of the firm's common stock from 100 million to 150 million.


Fluxion Biosciences said this week that it has launched its discovery services business, which will offer a range of cellular assays in ion channels using its IonFlux system, functional cell analysis using its BioFlux system, and circulating tumor cell analysis using its IsoFlux platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.

Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.

FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.

Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.